Interestingly, molecular docking and dynamics simulations suggested that apigenin and naringenin may act as potential multifunctional inhibitors for the future experimental therapy of DS because they may simultaneously inhibit CBS and DYRK1A [284]. The gene discussed is DYRK1A; the disease is Dravet syndrome.